Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 716
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT06306638 Interstitial Photodynamic Therapy Following Palliative Radiotherapy in … |
Biospecimen Collection | Cancer | Phase 1/2 | RECRUITING | En attente / non publié | Roswell Park Cancer Institute | United States · Abramson Cancer Center, Philadelphia,… | 2024-10-01 → 2029-10-01 | Ouvrir |
| NCT07623941 CUIMC Focal Therapy Registry |
Focal Therapy | Cancer | À vérifier | RECRUITING | En attente / non publié | Columbia University | United States · Columbia University Irving Medical Ce… | 2026-01-01 → 2040-12-31 | Ouvrir |
| NCT01833806 A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metast… |
ExAblate MRgFUS | Cancer | Non applicable | COMPLETED | En attente / non publié | InSightec | United States · City of Hope, Duarte, United States |… | 2013-09 → 2022-01-14 | Ouvrir |
| NCT01799499 NMIBC TURBT HG — A Prospective Open Label Comparative Dose Ranging Stud… |
TC-3 hydrogel | Cancer | Non applicable | WITHDRAWN | En attente / non publié | UroGen Pharma Ltd. | Israel · Western Galilee Hospital Nahariya, Nahariya,… | 2013-03 → 2013-03 | Ouvrir |
| NCT03484299 Chemotherapy and Irreversible Electroporation in the Treatment of Advan… |
Irreversible Electroporation (IRE) | Cancer | Phase 1 | RECRUITING | En attente / non publié | University of Louisville | United States · University of Louisville, Louisville,… | 2018-05-30 → 2027-07-31 | Ouvrir |
| NCT07263451 Safety and Feasibility of IRE for Early-stage Breast Cancer: a Prospect… |
IRE by stunning pulse therapy dev… | Cancer | Non applicable | RECRUITING | En attente / non publié | Tian'an Jiang | China · The First Affiliated Hospital, Zhejiang Unive… | 2025-12-11 → 2026-05-15 | Ouvrir |
| NCT05856838 RAMBOS — NovaSure Study: Endometrial Ablation in Women With Heavy Menst… |
NovaSure ablation | Cancer | Non applicable | RECRUITING | En attente / non publié | University Hospital, Ghent | Belgium · Ghent University Hospital, Ghent, Belgium | 2023-11-24 → 2026-12-31 | Ouvrir |
| NCT06715878 Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation… |
Zero Ischemia Robot-Assisted Lapa… | Cancer | Non applicable | RECRUITING | En attente / non publié | RenJi Hospital | China · Ethics Committee of Shanghai Renji Hospital, … | 2024-03-01 → 2025-12-31 | Ouvrir |
| NCT07873619 Histotripsy for Peritoneal Tumour and Lymph Node: a Pilot Study |
Histotripsie — HistoSonics Edison… | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Northwell Health | Hong Kong · The University of Hong Kong, Hong Kong, H… | 2026-10-01 → 2029-08-31 | Ouvrir |
| NCT06252584 AML-VAC-XS15 — Multi-peptide Vaccination Adjuvanted With XS15 in Acute … |
Vaccines, Peptide | Cancer | Phase 1 | RECRUITING | En attente / non publié | University Hospital Tuebingen | Germany · University Hospital Tuebingen, Tübingen, Ge… | 2024-06-10 → 2028-12-31 | Ouvrir |
| NCT03223610 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) i… |
Venetoclax | Cancer | Phase 1/2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · National Institutes of Health Clinica… | 2018-02-09 → 2029-12-12 | Ouvrir |
| NCT07227597 A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-… |
Gocatamig | Cancer | Phase 1/2 | RECRUITING | En attente / non publié | Merck Sharp & Dohme LLC | United States, Argentina, Chile, China, Germany, Gree… | 2026-01-29 → 2030-12-30 | Ouvrir |
| NCT06096779 Kirros — A Study Evaluating Atezolizumab, With or Without Bevacizumab, … |
Atezolizumab | Cancer | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Merck Sharp & Dohme LLC | United States, Puerto Rico · Barbara Ann Karmanos Can… | 2024-07-15 → 2027-12-30 | Ouvrir |
| NCT07217990 NoCUT-BC — Neoadjuvant Complete Response Customized Treatment Approach … |
Neoadjuvant Chemotherapy | Cancer | Phase 1/2 | NOT_YET_RECRUITING | En attente / non publié | Ohio State University Comprehensi… | United States · Ohio State University Comprehensive C… | 2027-01-15 → 2028-01-31 | Ouvrir |
| NCT06770582 Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radia… |
Biospecimen Collection | Cancer | Phase 2 | RECRUITING | En attente / non publié | Roswell Park Cancer Institute | United States, Canada · AIS Cancer Center at San Joaq… | 2025-06-03 → 2032-02-01 | Ouvrir |
| NCT07504588 Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (… |
Anti-VEGF Monoclonal Antibody | Cancer | Phase 2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · Benefis Sletten Cancer Institute, Gre… | 2026-09-24 → 2029-04-12 | Ouvrir |
| NCT05430373 GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumo… |
GT101 | Cancer | Phase 1 | ACTIVE_NOT_RECRUITING | En attente / non publié | Grit Biotechnology | China · Chongqing University Cancer Center, Chongqing… | 2022-05-23 → 2026-12-30 | Ouvrir |
| NCT06930352 Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rea… |
Biospecimen Collection | Cancer | Phase 2 | RECRUITING | En attente / non publié | Roswell Park Cancer Institute | United States · Ohio State University Comprehensive C… | 2027-01-15 → 2028-01-31 | Ouvrir |
| NCT02276885 Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial |
PBI Radiotherapy 6 Gy | Cancer | Non applicable | COMPLETED | En attente / non publié | NYU Langone Health | United States · NYU Langone Medical Center, New York,… | 2014-10-28 → 2026-07-20 | Ouvrir |
| NCT06260033 Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Trea… |
Biospecimen Collection | Cancer | Phase 2 | RECRUITING | En attente / non publié | Roswell Park Cancer Institute | United States · City of Hope at Irvine Lennar, Irvine… | 2024-07-23 → 2027-10-29 | Ouvrir |
| NCT05588141 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Glio… |
Zotiraciclib | Cancer | Phase 1/2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · Mayo Clinic Flordia, Jacksonville, Un… | 2023-05-16 → 2032-08-02 | Ouvrir |
| NCT07926542 DEX-EBUS — Dexmedetomidine as an add-on Sedative for Endobronchial Ultr… |
Dexmedetomidine | Cancer | Non applicable | COMPLETED | En attente / non publié | Centro Hospitalar de Lisboa Centr… | Portugal · João Freitas, Lisbon, Portugal | 2026-04-01 → 2026-07-31 | Ouvrir |
| NCT07389278 Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed Hi… |
ADI-PEG 20 (Arginine deiminase pe… | Cancer | Phase 1/2 | NOT_YET_RECRUITING | En attente / non publié | Sabine Mueller, MD, PhD | United States · University of California, San Francis… | 2027-06-01 → 2035-06-30 | Ouvrir |
| NCT01906385 Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes i… |
Rhenium Liposome Treatment | Cancer | Phase 1/2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Cerenome | United States · Northshore University Hospital, Manha… | 2015-06-03 → 2027-04 | Ouvrir |
| NCT07926048 A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian T… |
QLS5132 | Cancer | Phase 3 | NOT_YET_RECRUITING | En attente / non publié | Qilu Pharmaceutical Co., Ltd. | Non communiqué | 2026-12 → 2030-01 | Ouvrir |